Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Medtronic
Colorcon
Harvard Business School
Deloitte
Fuji
Teva
Moodys
Dow

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,884,439

« Back to Dashboard

Which drugs does patent 6,884,439 protect, and when does it expire?

Patent 6,884,439 protects TRISENOX and is included in one NDA.

This patent has twenty-two patent family members in eighteen countries.
Summary for Patent: 6,884,439
Title: Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Abstract:The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Inventor(s): Warrell, Jr.; Raymond P. (Westfield, NJ), Pandolfi; Pier Paolo (New York, NY), Gabrilove; Janice L. (New York, NY)
Assignee: Memorial Sloan-Kettering Cancer Center (New York, NY)
Application Number:10/759,291
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,884,439
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,884,439

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cephalon TRISENOX arsenic trioxide INJECTABLE;INJECTION 021248-001 Sep 25, 2000 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION ➤ Try a Free Trial
Cephalon TRISENOX arsenic trioxide INJECTABLE;INJECTION 021248-001 Sep 25, 2000 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) ➤ Try a Free Trial
Cephalon TRISENOX arsenic trioxide INJECTABLE;INJECTION 021248-001 Sep 25, 2000 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-A GENE EXPRESSION ➤ Try a Free Trial
Cephalon TRISENOX arsenic trioxide INJECTABLE;INJECTION 021248-002 Oct 13, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,884,439

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,273,379 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol ➤ Try a Free Trial
6,855,339 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol ➤ Try a Free Trial
6,723,351 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol ➤ Try a Free Trial
7,879,364 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,884,439

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey 200002243 ➤ Try a Free Trial
Portugal 2255800 ➤ Try a Free Trial
Portugal 1964557 ➤ Try a Free Trial
Poland 343868 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cantor Fitzgerald
Federal Trade Commission
Merck
McKinsey
Chubb
Johnson and Johnson
Teva
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.